Role of Epigenetics in Female Genital Tuberculosis patients

Role of Epigenetics in Female Genital Tuberculosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/12/022285

Enrollment

Registered

2019-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N739- Female pelvic inflammatory disease, unspecified Health Condition 2: N738- Other specified female pelvic inflammatory diseases

Interventions

Intervention1: LAMP LAM urine: LAMP and urine LAM test will be done Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: female infertile patients attending GOPD for Infertility treatment

Exclusion criteria

Exclusion criteria: Failure to meet all inclusion criteria Women having any gynecological malignancy Retreatment cases of FGTB

Design outcomes

Primary

Measure	Time frame
To elucidate the diagnostic modality for female genital tuberculosisTimepoint: after 2 years	—

Secondary

Measure	Time frame
to correlate the clinical outcome of the study with the clinico-pathological condition of the diseaseTimepoint: after 3 years	—

Countries

India

Contacts

Public ContactSona Dharmendra

All India Institute of Medical Sciences

jbsharma2000@gmail.com09868397309

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026